These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 24551200)

  • 1. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.
    Shao C; Liao CP; Hu P; Chu CY; Zhang L; Bui MH; Ng CS; Josephson DY; Knudsen B; Tighiouart M; Kim HL; Zhau HE; Chung LW; Wang R; Posadas EM
    PLoS One; 2014; 9(2):e88967. PubMed ID: 24551200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analogous detection of circulating tumor cells using the AccuCyte
    van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
    Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer.
    Dong L; Zhang Z; Smith K; Kuczler MD; Reyes D; Amend SR; Cho YK; Xue W; Pienta KJ
    BJU Int; 2020 Jul; 126(1):191-201. PubMed ID: 32115854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.
    Mandel PC; Huland H; Tiebel A; Haese A; Salomon G; Budäus L; Tilki D; Chun F; Heinzer H; Graefen M; Pantel K; Riethdorf S; Steuber T
    Eur Urol Focus; 2021 Jan; 7(1):55-62. PubMed ID: 31178293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NanoVelcro Chip for CTC enumeration in prostate cancer patients.
    Lu YT; Zhao L; Shen Q; Garcia MA; Wu D; Hou S; Song M; Xu X; Ouyang WH; Ouyang WW; Lichterman J; Luo Z; Xuan X; Huang J; Chung LW; Rettig M; Tseng HR; Shao C; Posadas EM
    Methods; 2013 Dec; 64(2):144-52. PubMed ID: 23816790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.
    Chen JF; Ho H; Lichterman J; Lu YT; Zhang Y; Garcia MA; Chen SF; Liang AJ; Hodara E; Zhau HE; Hou S; Ahmed RS; Luthringer DJ; Huang J; Li KC; Chung LW; Ke Z; Tseng HR; Posadas EM
    Cancer; 2015 Sep; 121(18):3240-51. PubMed ID: 25975562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
    Theil G; Fischer K; Weber E; Medek R; Hoda R; Lücke K; Fornara P
    PLoS One; 2016; 11(8):e0158354. PubMed ID: 27479125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acoustic Enrichment of Heterogeneous Circulating Tumor Cells and Clusters from Metastatic Prostate Cancer Patients.
    Magnusson C; Augustsson P; Undvall Anand E; Lenshof A; Josefsson A; Welén K; Bjartell A; Ceder Y; Lilja H; Laurell T
    Anal Chem; 2024 May; 96(18):6914-6921. PubMed ID: 38655666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.
    Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):358-64. PubMed ID: 26238233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.
    Zapatero A; Gómez-Caamaño A; Cabeza Rodriguez MÁ; Muinelo-Romay L; Martin de Vidales C; Abalo A; Calvo Crespo P; Leon Mateos L; Olivier C; Vega Piris LV
    Radiat Oncol; 2020 Jun; 15(1):137. PubMed ID: 32487218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
    Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
    Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application.
    Chen F; Wang S; Fang Y; Zheng L; Zhi X; Cheng B; Chen Y; Zhang C; Shi D; Song H; Cai C; Zhou P; Xiong B
    Oncotarget; 2017 Jan; 8(2):3029-3041. PubMed ID: 27935872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.
    Todenhöfer T; Park ES; Duffy S; Deng X; Jin C; Abdi H; Ma H; Black PC
    Urol Oncol; 2016 Nov; 34(11):483.e9-483.e16. PubMed ID: 27658563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status.
    Moreno JG; O'Hara SM; Gross S; Doyle G; Fritsche H; Gomella LG; Terstappen LW
    Urology; 2001 Sep; 58(3):386-92. PubMed ID: 11549486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.
    Kolostova K; Broul M; Schraml J; Cegan M; Matkowski R; Fiutowski M; Bobek V
    Anticancer Res; 2014 Jul; 34(7):3641-6. PubMed ID: 24982381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of rare circulating tumour cells in cancer patients by microchip technology.
    Nagrath S; Sequist LV; Maheswaran S; Bell DW; Irimia D; Ulkus L; Smith MR; Kwak EL; Digumarthy S; Muzikansky A; Ryan P; Balis UJ; Tompkins RG; Haber DA; Toner M
    Nature; 2007 Dec; 450(7173):1235-9. PubMed ID: 18097410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.